Doximity (DOCS) Financials

$66.19 -0.19 (-0.29%)

Closing price 10/23/2025 03:59 PM Eastern

Extended Trading

$64.62 -1.56 (-2.36%)

As of 10/23/2025 07:19 PM Eastern

Annual Income Statements for Doximity

This table shows Doximity's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Period end date	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024
Net Income / (Loss) Attributable to Common Shareholders	11	22	133	113	148
Consolidated Net Income / (Loss)	30	50	155	113	148
Net Income / (Loss) Continuing Operations	30	50	155	113	148
Total Pre-Tax Income	24	58	114	133	185
Total Operating Income	22	53	114	125	164
Total Gross Profit	101	176	304	366	425
Total Revenue	116	207	344	419	475
Operating Revenue	116	207	344	419	475
Total Cost of Revenue	15	31	40	53	51
Operating Cost of Revenue	15	31	40	53	51
Total Operating Expenses	79	122	190	240	261
Selling, General & Admin Expense	7.44	16	36	37	38
Marketing Expense	39	62	92	124	133
Research & Development Expense	32	44	62	80	82
Restructuring Charge	-	-	0.00	0.00	7.94
Total Other Income / (Expense), net	1.35	4.47	0.47	8.05	21
Other Income / (Expense), net	1.35	4.47	0.47	8.05	21
Income Tax Expense	-6.22	7.56	-41	20	38
Net Income / (Loss) Attributable to Noncontrolling Interest	19	29	22	0.00	0.00
Basic Earnings per Share	$0.16	$0.29	$0.82	$0.58	$0.78
Weighted Average Basic Shares Outstanding	66.76M	74.34M	163.48M	193.18M	190.17M
Diluted Earnings per Share	$0.13	$0.23	$0.70	$0.53	$0.72
Weighted Average Diluted Shares Outstanding	81.71M	95.13M	191.02M	213.43M	205.73M
Weighted Average Basic & Diluted Shares Outstanding	-	-	193.11M	194.67M	185.43M

This table shows Doximity's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	22	26	33	31	28	31	48	41	41	44	75
Consolidated Net Income / (Loss)	22	26	33	31	28	31	48	41	41	44	75
Net Income / (Loss) Continuing Operations	22	26	33	31	28	31	48	41	41	44	75
Total Pre-Tax Income	22	33	41	37	35	40	63	48	53	62	90
Total Operating Income	22	32	38	33	30	34	59	42	46	53	80
Total Gross Profit	78	89	102	97	95	101	123	105	113	123	154
Total Revenue	91	102	115	111	108	114	135	118	127	137	169
Operating Revenue	91	102	115	111	108	114	135	118	127	137	169
Total Cost of Revenue	13	13	14	14	13	13	12	13	14	14	14
Operating Cost of Revenue	13	13	14	14	13	13	12	13	14	14	14
Total Operating Expenses	56	57	63	64	66	67	65	64	67	70	74
Selling, General & Admin Expense	8.72	8.75	9.51	9.76	9.25	8.97	9.64	9.97	9.26	10	14
Marketing Expense	28	29	33	33	34	30	35	34	35	34	38
Research & Development Expense	19	19	21	22	22	20	20	20	23	23	22
Restructuring Charge	-	0.00	0.00	-	-	7.94	0.00	-	-	2.30	0.00
Total Other Income / (Expense), net	0.80	0.91	2.46	3.88	4.84	5.90	4.48	6.10	7.12	9.03	9.92
Income Tax Expense	0.10	6.71	7.48	6.05	6.12	9.09	15	7.34	12	18	15
Basic Earnings per Share	$0.12	$0.14	$0.17	$0.15	$0.15	$0.16	$0.26	$0.21	$0.22	$0.24	$0.40
Weighted Average Basic Shares Outstanding	192.95M	193.14M	192.81M	193.18M	194.52M	193.11M	186.31M	190.17M	185.61M	186.25M	187.16M
Diluted Earnings per Share	$0.10	$0.12	$0.16	$0.15	$0.13	$0.15	$0.24	$0.20	$0.21	$0.22	$0.37
Weighted Average Diluted Shares Outstanding	214.95M	213.95M	212.07M	213.43M	212.36M	209.01M	200.46M	205.73M	199.22M	200.41M	202.23M
Weighted Average Basic & Diluted Shares Outstanding	193.46M	192.49M	193.59M	194.67M	194.71M	185.91M	186.55M	185.43M	185.66M	186.69M	187.64M

This table details how cash moves in and out of Doximity's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Period end date	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024
Net Change in Cash & Equivalents	15	18	46	45	-61
Net Cash From Operating Activities	26	83	127	180	184
Net Cash From Continuing Operating Activities	26	83	127	180	184
Net Income / (Loss) Continuing Operations	30	50	155	113	148
Consolidated Net Income / (Loss)	30	50	155	113	148
Depreciation Expense	0.90	3.70	5.04	10	10
Amortization Expense	4.63	7.08	14	12	3.63
Non-Cash Adjustments To Reconcile Net Income	4.30	5.39	34	52	55
Changes in Operating Assets and Liabilities, net	-13	17	-82	-7.08	-32
Net Cash From Investing Activities	-13	-70	-641	-60	31
Net Cash From Continuing Investing Activities	-13	-70	-641	-60	31
Purchase of Property, Plant & Equipment	-4.24	-4.61	-5.70	-6.18	-5.80
Acquisitions	0.00	-32	0.00	-54	0.00
Purchase of Investments	-79	-79	-1,317	-191	-473
Sale and/or Maturity of Investments	70	41	682	190	510
Other Investing Activities, net	0.00	-0.01	0.60	0.00	0.00
Net Cash From Financing Activities	1.72	5.41	560	-74	-277
Net Cash From Continuing Financing Activities	1.72	5.41	560	-74	-277
Repurchase of Common Equity	0.00	-3.49	-6.68	-85	-281
Issuance of Common Equity	0.00	8.90	568	15	16
Other Financing Activities, net	1.72	0.00	-0.82	-3.82	-12
Cash Income Taxes Paid	1.24	5.97	0.21	5.23	51

This table details how cash moves in and out of Doximity's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-2.72	-36	63	22	149	-198	15	-26	15	73	-19
Net Cash From Operating Activities	45	40	49	47	57	13	50	64	41	68	65
Net Cash From Continuing Operating Activities	45	40	49	47	57	13	50	65	41	68	65
Net Income / (Loss) Continuing Operations	22	26	33	31	28	31	48	41	41	44	75
Consolidated Net Income / (Loss)	22	26	33	31	28	31	48	41	41	44	75
Depreciation Expense	2.37	2.59	2.62	2.71	2.60	2.60	2.51	2.55	2.56	2.61	2.66
Amortization Expense	4.22	3.29	1.99	2.40	2.37	0.57	-0.14	0.83	0.37	-0.98	-1.58
Non-Cash Adjustments To Reconcile Net Income	9.91	12	16	14	14	14	13	13	17	21	20
Changes in Operating Assets and Liabilities, net	5.86	-4.86	-5.17	-2.92	9.43	-35	-13	7.61	-20	1.30	-31
Net Cash From Investing Activities	-42	-19	13	-13	117	-50	40	-76	30	24	-59
Net Cash From Continuing Investing Activities	-42	-19	13	-13	117	-50	40	-76	30	24	-59
Purchase of Property, Plant & Equipment	-2.13	-1.82	-1.22	-1.03	-1.56	-1.28	-1.32	-1.63	-1.70	-1.54	-1.77
Purchase of Investments	-8.87	-82	-39	-60	-35	-145	-101	-192	-170	-197	-164
Sale and/or Maturity of Investments	23	66	54	48	154	96	143	117	202	223	107
Net Cash From Financing Activities	-5.97	-57	0.78	-12	-26	-161	-76	-14	-57	-20	-25
Net Cash From Continuing Financing Activities	-5.97	-57	0.78	-12	-26	-161	-76	-14	-57	-20	-25
Repurchase of Common Equity	-8.87	-61	-	-15	-22	-164	-77	-18	-51	-23	-19
Issuance of Common Equity	3.01	4.91	1.87	4.89	3.29	5.43	2.54	5.09	2.55	9.11	3.66
Other Financing Activities, net	-0.11	-1.15	-1.09	-1.47	-7.35	-2.12	-1.25	-1.42	-7.86	-5.83	-9.60
Cash Income Taxes Paid	0.00	0.12	2.38	2.73	0.00	29	8.93	13	13	9.08	14

This table presents Doximity's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024
Period end date	3/31/2021	3/31/2022	3/31/2023	3/31/2024
Total Assets	252	991	1,137	1,079
Total Current Assets	209	904	975	913
Cash & Equivalents	66	113	158	97
Short-Term Investments	76	685	683	666
Accounts Receivable	50	81	107	101
Prepaid Expenses	11	19	27	49
Plant, Property, & Equipment, net	7.60	8.49	11	12
Total Noncurrent Assets	35	79	150	154
Goodwill	19	19	68	68
Intangible Assets	9.60	7.91	32	27
Noncurrent Deferred & Refundable Income Taxes	2.11	49	35	45
Other Noncurrent Operating Assets	4.10	3.35	15	14
Total Liabilities & Shareholders' Equity	252	991	1,137	1,079
Total Liabilities	104	113	171	178
Total Current Liabilities	102	111	140	147
Accounts Payable	1.52	0.46	1.27	2.25
Accrued Expenses	16	25	31	44
Current Deferred Revenue	83	85	105	99
Other Current Liabilities	0.97	0.64	1.75	2.15
Total Noncurrent Liabilities	1.48	1.48	31	31
Noncurrent Deferred Revenue	0.22	0.08	0.20	0.21
Other Noncurrent Operating Liabilities	1.26	1.40	31	31
Commitments & Contingencies	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	67	879	966	901
Total Preferred & Common Equity	67	879	966	901
Preferred Stock	0.00	0.00	0.00	0.00
Total Common Equity	67	879	966	901
Common Stock	30	703	762	824
Retained Earnings	36	191	218	80
Accumulated Other Comprehensive Income / (Loss)	-0.02	-15	-14	-2.66

This table presents Doximity's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	12/31/2021	6/30/2022	9/30/2022	12/31/2022	6/30/2023	9/30/2023	12/31/2023	6/30/2024	9/30/2024	12/31/2024
Total Assets	932	1,051	1,028	1,067	1,154	1,026	1,001	1,073	1,119	1,172
Total Current Assets	858	874	848	899	990	863	841	908	958	1,013
Cash & Equivalents	85	110	74	136	307	108	123	111	184	165
Short-Term Investments	680	666	676	665	566	621	587	639	621	680
Accounts Receivable	70	76	79	75	93	97	98	121	125	138
Prepaid Expenses	18	18	16	17	20	33	27	37	27	30
Plant, Property, & Equipment, net	8.22	11	12	12	12	12	12	13	13	13
Total Noncurrent Assets	66	165	169	157	152	151	148	152	148	146
Goodwill	19	68	68	68	68	68	68	68	68	68
Intangible Assets	8.80	35	34	33	31	29	28	26	25	24
Noncurrent Deferred & Refundable Income Taxes	35	49	51	40	39	39	37	45	44	43
Other Noncurrent Operating Assets	2.43	13	16	16	15	14	14	13	11	11
Total Liabilities & Shareholders' Equity	932	1,051	1,028	1,067	1,154	1,026	1,001	1,073	1,119	1,172
Total Liabilities	93	149	149	137	163	154	136	160	157	141
Total Current Liabilities	92	121	118	106	133	123	105	135	132	116
Accounts Payable	1.23	0.92	1.11	1.60	0.58	0.71	1.88	1.66	2.77	1.64
Accrued Expenses	24	25	26	33	32	29	34	28	34	43
Current Deferred Revenue	66	94	90	70	98	91	67	103	94	69
Other Current Liabilities	0.93	0.68	1.01	1.46	2.05	1.94	2.11	2.19	2.22	2.26
Total Noncurrent Liabilities	1.61	28	31	31	30	31	31	25	25	25
Noncurrent Deferred Revenue	0.04	0.20	0.17	0.14	0.19	0.24	0.17	0.12	0.15	0.07
Other Noncurrent Operating Liabilities	1.57	28	31	31	30	31	25	24	25	25
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	839	902	879	930	991	871	865	914	961	1,031
Total Preferred & Common Equity	839	902	879	930	991	871	865	914	961	1,031
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	839	902	879	930	991	871	865	914	961	1,031
Common Stock	688	715	731	746	778	795	808	842	863	879
Retained Earnings	154	205	170	203	225	85	61	73	95	151
Accumulated Other Comprehensive Income / (Loss)	-4.01	-18	-22	-19	-12	-8.93	-4.65	-1.01	2.68	1.02

This table displays calculated financial ratios and metrics derived from Doximity's official financial filings.

Metric	2020	2021	2022	2023	2024
Period end date	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	77.76%	66.05%	21.98%	13.45%
EBITDA Growth	0.00%	136.03%	94.21%	16.68%	28.17%
EBIT Growth	0.00%	145.68%	97.35%	16.80%	39.09%
NOPAT Growth	0.00%	65.29%	232.73%	-31.23%	23.20%
Net Income Growth	0.00%	68.85%	208.27%	-27.11%	30.81%
EPS Growth	0.00%	76.92%	204.35%	-24.29%	35.85%
Operating Cash Flow Growth	0.00%	216.70%	52.55%	41.89%	2.50%
Free Cash Flow Firm Growth	0.00%	0.00%	95.10%	-22.65%	91.01%
Invested Capital Growth	0.00%	0.00%	1,320.17%	55.46%	10.69%
Revenue Q/Q Growth	0.00%	0.00%	8.52%	4.31%	1.51%
EBITDA Q/Q Growth	0.00%	0.00%	5.32%	9.02%	16.78%
EBIT Q/Q Growth	0.00%	0.00%	4.41%	10.79%	19.59%
NOPAT Q/Q Growth	0.00%	0.00%	11.00%	-7.75%	6.58%
Net Income Q/Q Growth	0.00%	0.00%	10.92%	-5.10%	7.23%
EPS Q/Q Growth	0.00%	0.00%	2.94%	-5.36%	7.46%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	8.03%	-0.18%	10.38%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	4.07%	20.39%
Invested Capital Q/Q Growth	0.00%	0.00%	9.84%	-3.17%	-10.29%
Profitability Metrics	-	-	-	-	-
Gross Margin	87.20%	84.92%	88.42%	87.24%	89.34%
EBITDA Margin	24.95%	33.13%	38.75%	37.07%	41.88%
Operating Margin	19.04%	25.76%	33.05%	29.86%	34.47%
EBIT Margin	20.20%	27.92%	33.18%	31.78%	38.96%
Profit (Net Income) Margin	25.55%	24.27%	45.05%	26.92%	31.04%
Tax Burden Percent	126.47%	86.92%	135.77%	84.73%	79.69%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	-26.47%	13.08%	-35.77%	15.27%	20.31%
Return on Invested Capital (ROIC)	0.00%	1,635.02%	357.86%	103.11%	99.08%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	1,629.58%	357.73%	102.28%	96.96%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-1,567.26%	-327.72%	-90.88%	-83.27%
Return on Equity (ROE)	0.00%	67.76%	30.15%	12.23%	15.81%
Cash Return on Invested Capital (CROIC)	0.00%	1,435.02%	184.18%	59.69%	88.93%
Operating Return on Assets (OROA)	0.00%	22.95%	18.34%	12.51%	16.71%
Return on Assets (ROA)	0.00%	19.95%	24.90%	10.60%	13.32%
Return on Common Equity (ROCE)	0.00%	30.52%	27.76%	12.23%	15.81%
Return on Equity Simple (ROE_SIMPLE)	0.00%	75.23%	17.62%	11.68%	16.37%
Net Operating Profit after Tax (NOPAT)	28	46	154	106	131
NOPAT Margin	24.08%	22.39%	44.87%	25.30%	27.47%
Net Nonoperating Expense Percent (NNEP)	0.00%	5.45%	0.14%	0.83%	2.12%
Cost of Revenue to Revenue	12.80%	15.08%	11.58%	12.76%	10.66%
SG&A Expenses to Revenue	6.39%	7.97%	10.41%	8.77%	7.96%
R&D to Revenue	27.87%	21.21%	18.15%	19.14%	17.24%
Operating Expenses to Revenue	68.16%	59.16%	55.37%	57.38%	54.87%
Earnings before Interest and Taxes (EBIT)	24	58	114	133	185
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	29	69	133	155	199
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	9.08	11.34	6.49	5.57
Price to Tangible Book Value (P/TBV)	0.00	15.85	11.70	7.24	6.23
Price to Revenue (P/Rev)	5.21	2.93	29.01	14.96	10.56
Price to Earnings (P/E)	55.94	28.10	74.78	55.56	34.02
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.79%	3.56%	1.34%	1.80%	2.94%
Enterprise Value to Invested Capital (EV/IC)	0.00	96.12	113.91	43.38	30.74
Enterprise Value to Revenue (EV/Rev)	0.00	2.63	26.68	12.95	8.95
Enterprise Value to EBITDA (EV/EBITDA)	0.00	7.95	68.86	34.94	21.38
Enterprise Value to EBIT (EV/EBIT)	0.00	9.43	80.41	40.76	22.99
Enterprise Value to NOPAT (EV/NOPAT)	0.00	11.76	59.47	51.20	32.60
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	6.57	72.43	30.22	23.13
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	13.40	115.56	88.45	36.32
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.96	-0.92	-0.89	-0.86
Leverage Ratio	0.00	1.70	1.21	1.15	1.19
Compound Leverage Factor	0.00	1.70	1.21	1.15	1.19
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	54.96%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	45.04%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	5.80	54.98	23.93	18.89
Noncontrolling Interest Sharing Ratio	0.00%	54.96%	7.93%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	0.00	2.05	8.12	6.99	6.20
Quick Ratio	0.00	1.89	7.90	6.80	5.87
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	41	79	61	117
Operating Cash Flow to CapEx	617.32%	1,799.85%	2,221.78%	2,904.30%	3,173.52%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	0.82	0.55	0.39	0.43
Accounts Receivable Turnover	0.00	4.11	5.23	4.46	4.56
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	27.23	42.71	42.40	40.30
Accounts Payable Turnover	0.00	20.59	40.23	61.66	28.75
Days Sales Outstanding (DSO)	0.00	88.77	69.80	81.93	79.99
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	17.73	9.07	5.92	12.70
Cash Conversion Cycle (CCC)	0.00	71.05	60.73	76.01	67.29
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	0.00	5.67	80	125	138
Invested Capital Turnover	0.00	73.02	7.98	4.08	3.61
Increase / (Decrease) in Invested Capital	0.00	5.67	75	45	13
Enterprise Value (EV)	0.00	545	9,167	5,427	4,257
Market Capitalization	606	606	9,966	6,268	5,020
Book Value per Share	$0.00	$0.90	$4.59	$4.99	$4.83
Tangible Book Value per Share	$0.00	$0.51	$4.45	$4.48	$4.32
Total Capital	0.00	148	879	966	901
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-143	-798	-841	-763
Capital Expenditures (CapEx)	4.24	4.61	5.70	6.18	5.80
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-35	-5.26	-5.05	2.79
Debt-free Net Working Capital (DFNWC)	0.00	107	793	836	766
Net Working Capital (NWC)	0.00	107	793	836	766
Net Nonoperating Expense (NNE)	-1.71	-3.88	-0.64	-6.82	-17
Net Nonoperating Obligations (NNO)	0.00	-143	-798	-841	-763
Total Depreciation and Amortization (D&A)	5.53	11	19	22	14
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-17.00%	-1.53%	-1.21%	0.59%
Debt-free Net Working Capital to Revenue	0.00%	51.89%	230.78%	199.49%	161.06%
Net Working Capital to Revenue	0.00%	51.89%	230.78%	199.49%	161.06%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.82	$0.58	$0.78
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	163.48M	193.18M	190.17M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.70	$0.53	$0.72
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	191.02M	213.43M	205.73M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	193.11M	194.67M	185.43M
Normalized Net Operating Profit after Tax (NOPAT)	16	46	79	106	137
Normalized NOPAT Margin	13.33%	22.39%	23.13%	25.30%	28.80%
Pre Tax Income Margin	20.20%	27.92%	33.18%	31.78%	38.96%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	6.95%	4.32%	75.63%	190.21%

This table displays calculated financial ratios and metrics derived from Doximity's official financial filings.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	24.73%	28.78%	17.76%	18.49%	19.67%	11.18%	17.37%	6.39%	16.79%	20.44%	24.63%
EBITDA Growth	-4.40%	25.57%	7.23%	14.54%	22.57%	-2.68%	41.39%	19.19%	41.34%	48.20%	32.95%
EBIT Growth	-12.99%	26.53%	7.47%	17.69%	36.90%	5.27%	52.14%	27.44%	55.15%	57.26%	36.50%
NOPAT Growth	-17.86%	-27.94%	-43.44%	-25.35%	13.17%	1.86%	41.61%	29.23%	46.74%	44.87%	50.17%
Net Income Growth	-14.96%	-27.13%	-39.86%	-16.50%	26.91%	16.36%	43.29%	32.44%	45.66%	44.28%	56.80%
EPS Growth	11.11%	-29.41%	-38.46%	-16.67%	30.00%	25.00%	50.00%	33.33%	61.54%	46.67%	54.17%
Operating Cash Flow Growth	34.90%	106.32%	78.48%	-0.69%	27.82%	-67.36%	2.79%	37.10%	-27.90%	429.90%	30.24%
Free Cash Flow Firm Growth	-521.52%	-1,414.45%	-38.68%	54.80%	131.98%	118.25%	179.16%	228.28%	-129.46%	76.84%	81.08%
Invested Capital Growth	6,201.90%	331.36%	76.35%	55.46%	-6.59%	9.80%	19.48%	10.69%	38.67%	9.90%	20.60%
Revenue Q/Q Growth	-3.22%	12.74%	12.80%	-3.73%	-2.25%	4.74%	19.08%	-12.73%	7.30%	8.02%	23.22%
EBITDA Q/Q Growth	-14.66%	34.33%	13.45%	-11.93%	-8.68%	6.66%	64.82%	-25.76%	8.29%	11.84%	47.86%
EBIT Q/Q Growth	-22.30%	48.05%	19.88%	-14.66%	-9.62%	13.84%	73.27%	-28.52%	10.04%	15.39%	50.40%
NOPAT Q/Q Growth	-41.27%	18.50%	22.99%	-12.80%	-10.96%	6.66%	71.00%	-20.42%	1.10%	5.31%	77.25%
Net Income Q/Q Growth	-39.05%	17.50%	27.26%	-8.37%	-7.38%	7.73%	56.71%	-15.30%	1.87%	6.71%	70.30%
EPS Q/Q Growth	-44.44%	20.00%	33.33%	-6.25%	-13.33%	15.38%	60.00%	-16.67%	5.00%	4.76%	68.18%
Operating Cash Flow Q/Q Growth	-4.71%	-11.70%	23.24%	-4.23%	22.64%	-77.45%	288.08%	27.75%	-35.50%	65.72%	-4.62%
Free Cash Flow Firm Q/Q Growth	-168.82%	28.18%	66.69%	29.73%	290.19%	-59.02%	44.50%	13.88%	-143.67%	346.05%	47.97%
Invested Capital Q/Q Growth	56.45%	2.43%	0.18%	-3.17%	-6.00%	20.40%	9.01%	-10.29%	17.76%	-4.57%	19.62%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	85.57%	87.07%	88.27%	87.67%	87.87%	88.77%	90.99%	89.36%	89.30%	90.01%	91.59%
EBITDA Margin	31.19%	37.17%	37.38%	34.20%	31.95%	32.54%	45.03%	38.31%	38.67%	40.03%	48.04%
Operating Margin	23.92%	31.41%	33.39%	29.60%	27.37%	29.74%	43.28%	35.45%	36.36%	38.84%	47.40%
EBIT Margin	23.92%	31.41%	33.39%	29.60%	27.37%	29.74%	43.28%	35.45%	36.36%	38.84%	47.40%
Profit (Net Income) Margin	24.69%	25.74%	29.04%	27.64%	26.19%	26.94%	35.45%	34.41%	32.66%	32.27%	44.60%
Tax Burden Percent	99.54%	79.67%	81.74%	83.53%	82.28%	77.09%	76.08%	84.70%	77.82%	71.02%	83.70%
Interest Burden Percent	103.71%	102.83%	106.39%	111.80%	116.30%	117.47%	107.65%	114.58%	115.45%	116.99%	112.41%
Effective Tax Rate	0.46%	20.33%	18.26%	16.47%	17.72%	22.91%	23.92%	15.30%	22.18%	28.98%	16.30%
Return on Invested Capital (ROIC)	134.60%	121.10%	108.30%	100.77%	80.79%	75.98%	108.76%	108.31%	99.50%	95.92%	128.20%
ROIC Less NNEP Spread (ROIC-NNEP)	134.49%	121.01%	108.04%	100.38%	80.31%	75.37%	108.31%	107.67%	98.82%	95.08%	127.13%
Return on Net Nonoperating Assets (RNNOA)	-123.94%	-109.36%	-95.67%	-89.19%	-69.98%	-63.72%	-91.20%	-92.47%	-84.26%	-79.66%	-104.29%
Return on Equity (ROE)	10.66%	11.74%	12.62%	11.58%	10.81%	12.27%	17.56%	15.84%	15.25%	16.26%	23.91%
Cash Return on Invested Capital (CROIC)	39.51%	50.29%	58.24%	59.69%	96.29%	71.44%	68.66%	88.93%	68.75%	93.87%	84.54%
Operating Return on Assets (OROA)	9.19%	12.73%	13.42%	11.65%	10.85%	12.98%	19.61%	15.21%	16.12%	18.72%	24.01%
Return on Assets (ROA)	9.49%	10.43%	11.67%	10.88%	10.38%	11.76%	16.06%	14.76%	14.48%	15.56%	22.59%
Return on Common Equity (ROCE)	10.66%	11.74%	12.62%	11.58%	10.81%	12.27%	17.56%	15.84%	15.25%	16.26%	23.91%
Return on Equity Simple (ROE_SIMPLE)	16.72%	16.05%	12.78%	0.00%	11.99%	14.13%	15.92%	0.00%	17.57%	18.11%	19.53%
Net Operating Profit after Tax (NOPAT)	22	26	31	27	24	26	45	35	36	38	67
NOPAT Margin	23.81%	25.03%	27.29%	24.72%	22.52%	22.93%	32.93%	30.03%	28.29%	27.58%	39.68%
Net Nonoperating Expense Percent (NNEP)	0.11%	0.10%	0.26%	0.39%	0.48%	0.62%	0.45%	0.64%	0.68%	0.84%	1.07%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	5.15%	-	-	-	6.49%
Cost of Revenue to Revenue	14.43%	12.93%	11.74%	12.33%	12.13%	11.23%	9.01%	10.64%	10.70%	9.99%	8.41%
SG&A Expenses to Revenue	9.63%	8.56%	8.25%	8.79%	8.53%	7.89%	7.13%	8.45%	7.31%	7.38%	8.06%
R&D to Revenue	20.99%	18.70%	17.80%	19.41%	20.22%	17.57%	14.74%	17.07%	17.82%	16.98%	13.30%
Operating Expenses to Revenue	61.65%	55.66%	54.88%	58.08%	60.51%	59.03%	47.71%	53.90%	52.95%	51.17%	44.18%
Earnings before Interest and Taxes (EBIT)	22	32	38	33	30	34	59	42	46	53	80
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	28	38	43	38	35	37	61	45	49	55	81
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.45	6.65	6.94	6.49	6.68	4.74	6.03	5.57	5.68	8.42	9.67
Price to Tangible Book Value (P/TBV)	8.42	7.53	7.79	7.24	7.42	5.34	6.79	6.23	6.33	9.32	10.61
Price to Revenue (P/Rev)	18.60	15.21	16.08	14.96	15.16	9.22	11.13	10.56	10.51	15.65	18.12
Price to Earnings (P/E)	46.41	43.27	57.20	55.56	55.73	33.55	37.88	34.02	32.30	46.46	49.50
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.15%	2.31%	1.75%	1.80%	1.79%	2.98%	2.64%	2.94%	3.10%	2.15%	2.02%
Enterprise Value to Invested Capital (EV/IC)	47.24	39.52	43.80	43.38	48.88	24.02	29.17	30.74	27.20	46.80	49.00
Enterprise Value to Revenue (EV/Rev)	16.45	13.26	14.09	12.95	13.16	7.59	9.61	8.95	8.99	14.09	16.58
Enterprise Value to EBITDA (EV/EBITDA)	45.26	36.52	39.71	34.94	37.41	22.29	26.41	21.38	23.09	34.70	39.66
Enterprise Value to EBIT (EV/EBIT)	53.90	43.38	47.08	40.76	43.19	25.24	29.07	22.99	24.61	36.49	41.28
Enterprise Value to NOPAT (EV/NOPAT)	39.87	36.66	49.25	51.20	52.77	31.13	36.75	32.60	31.25	47.44	51.90
Enterprise Value to Operating Cash Flow (EV/OCF)	43.05	32.15	31.45	30.22	29.94	20.56	27.00	23.13	26.38	32.58	38.21
Enterprise Value to Free Cash Flow (EV/FCFF)	235.37	127.57	95.97	88.45	49.04	35.20	46.25	36.32	45.97	52.21	63.37
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.92	-0.90	-0.89	-0.89	-0.87	-0.85	-0.84	-0.86	-0.85	-0.84	-0.82
Leverage Ratio	1.15	1.15	1.13	1.15	1.16	1.17	1.15	1.19	1.17	1.17	1.15
Compound Leverage Factor	1.20	1.18	1.20	1.29	1.35	1.38	1.24	1.36	1.35	1.37	1.29
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	28.66	25.04	29.96	23.64	26.05	17.61	24.62	18.45	21.02	32.48	44.20
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.24	7.18	8.49	6.99	7.46	7.00	8.03	6.20	6.72	7.24	8.74
Quick Ratio	7.06	7.02	8.27	6.80	7.28	6.71	7.71	5.87	6.44	7.03	8.48
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-102	-73	-24	-17	33	13	19	22	-9.64	24	35
Operating Cash Flow to CapEx	2,105.98%	2,174.68%	4,004.69%	4,545.71%	3,657.29%	1,008.44%	3,780.51%	3,913.34%	2,420.36%	4,429.42%	3,680.91%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.38	0.41	0.40	0.39	0.40	0.44	0.45	0.43	0.44	0.48	0.51
Accounts Receivable Turnover	5.93	5.70	5.55	4.46	5.17	5.08	5.43	4.56	4.62	4.66	4.68
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	37.98	39.12	40.70	42.40	37.96	38.27	40.10	40.30	40.28	42.02	43.46
Accounts Payable Turnover	24.82	52.08	36.40	61.66	71.52	58.37	29.72	28.75	45.64	29.84	30.70
Days Sales Outstanding (DSO)	61.59	64.06	65.73	81.93	70.57	71.83	67.20	79.99	79.06	78.39	77.98
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	14.70	7.01	10.03	5.92	5.10	6.25	12.28	12.70	8.00	12.23	11.89
Cash Conversion Cycle (CCC)	46.89	57.05	55.70	76.01	65.47	65.58	54.92	67.29	71.06	66.16	66.09
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	126	129	129	125	118	142	154	138	163	156	186
Invested Capital Turnover	5.65	4.84	3.97	4.08	3.59	3.31	3.30	3.61	3.52	3.48	3.23
Increase / (Decrease) in Invested Capital	124	99	56	45	-8.30	13	25	13	45	14	32
Enterprise Value (EV)	5,948	5,096	5,659	5,427	5,749	3,402	4,503	4,257	4,436	7,284	9,123
Market Capitalization	6,724	5,846	6,460	6,268	6,623	4,132	5,213	5,020	5,186	8,089	9,967
Book Value per Share	$4.67	$4.54	$4.83	$4.99	$5.09	$4.48	$4.65	$4.83	$4.93	$5.18	$5.52
Tangible Book Value per Share	$4.14	$4.02	$4.31	$4.48	$4.58	$3.98	$4.13	$4.32	$4.42	$4.68	$5.03
Total Capital	902	879	930	966	991	871	865	901	914	961	1,031
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-776	-750	-801	-841	-873	-730	-710	-763	-750	-806	-845
Capital Expenditures (CapEx)	2.13	1.82	1.22	1.03	1.56	1.28	1.32	1.63	1.70	1.54	1.77
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-23	-20	-8.33	-5.05	-16	9.79	26	2.79	23	20	52
Debt-free Net Working Capital (DFNWC)	753	730	793	836	857	740	736	766	773	825	897
Net Working Capital (NWC)	753	730	793	836	857	740	736	766	773	825	897
Net Nonoperating Expense (NNE)	-0.80	-0.72	-2.01	-3.24	-3.98	-4.55	-3.41	-5.17	-5.54	-6.41	-8.30
Net Nonoperating Obligations (NNO)	-776	-750	-801	-841	-873	-730	-710	-763	-750	-806	-845
Total Depreciation and Amortization (D&A)	6.59	5.88	4.61	5.11	4.97	3.17	2.37	3.38	2.93	1.64	1.07
Debt-free, Cash-free Net Working Capital to Revenue	-6.32%	-5.26%	-2.07%	-1.21%	-3.71%	2.18%	5.53%	0.59%	4.60%	3.84%	9.43%
Debt-free Net Working Capital to Revenue	208.40%	189.87%	197.30%	199.49%	196.15%	164.98%	157.18%	161.06%	156.63%	159.70%	163.01%
Net Working Capital to Revenue	208.40%	189.87%	197.30%	199.49%	196.15%	164.98%	157.18%	161.06%	156.63%	159.70%	163.01%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.12	$0.14	$0.17	$0.15	$0.15	$0.16	$0.26	$0.21	$0.22	$0.24	$0.40
Adjusted Weighted Average Basic Shares Outstanding	192.95M	193.14M	192.81M	193.18M	194.52M	193.11M	186.31M	190.17M	185.61M	186.25M	187.16M
Adjusted Diluted Earnings per Share	$0.10	$0.12	$0.16	$0.15	$0.13	$0.15	$0.24	$0.20	$0.21	$0.22	$0.37
Adjusted Weighted Average Diluted Shares Outstanding	214.95M	213.95M	212.07M	213.43M	212.36M	209.01M	200.46M	205.73M	199.22M	200.41M	202.23M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	193.46M	192.49M	193.59M	194.67M	194.71M	185.91M	186.55M	185.43M	185.66M	186.69M	187.64M
Normalized Net Operating Profit after Tax (NOPAT)	22	26	31	27	24	32	45	35	36	39	67
Normalized NOPAT Margin	23.81%	25.03%	27.29%	24.72%	22.52%	28.32%	32.93%	30.03%	28.29%	28.78%	39.68%
Pre Tax Income Margin	24.81%	32.30%	35.52%	33.09%	31.83%	34.94%	46.59%	40.62%	41.97%	45.44%	53.28%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	7.35%	49.66%	58.92%	75.63%	82.64%	163.60%	202.18%	190.21%	193.19%	96.91%	55.25%

Financials Breakdown Chart

Key Financial Trends

Over the past four years, Doximity, Inc. (NASDAQ: DOCS) has demonstrated a consistent trend of revenue growth and profitability, supported by disciplined operating expense management and solid cash flow generation. Here are the key trends and highlights from the quarterly financials covering Q3 2022 through Q3 2025:

Revenue Growth: Doximity's operating revenue increased steadily from approximately $90.6 million in Q1 2023 to $168.6 million in Q3 2025, nearly doubling over this period. This indicates strong market adoption and expanded customer engagement.
Improved Profitability: Net income rose significantly, from $22.4 million in Q1 2023 to $75.2 million in Q3 2025. Earnings per share (diluted) increased from $0.10 to $0.37, reflecting both growth in earnings and effective share management.
Robust Operating Margins: Total gross profit margin remained healthy, exceeding 90% in recent quarters. Operating income improved substantially with operating expenses controlled relative to revenue growth.
Strong Cash Flow from Operations: Quarterly cash flow from operations increased from about $44.8 million in Q1 2023 to around $65.2 million in Q3 2025, indicating strong cash generation capability to support operations and investments.
Healthy Balance Sheet Position: Total assets increased from approximately $1.05 billion in Q1 2023 to $1.17 billion in Q3 2025. The company holds sizable cash and short-term investments (over $800 million), providing good liquidity and financial flexibility.
Increasing Marketing and R&D Expenses: Marketing expenses rose from about $28 million in early 2023 to nearly $38.5 million by Q3 2025, while research & development costs increased moderately. This suggests continued investment in growth and innovation, which may pressure margins in the short term but potentially supports future revenue expansion.
Share Repurchases: The company has periodically repurchased shares with outflows of $8.9 million to over $51 million per quarter historically, demonstrating confidence in the business but also impacting cash balances.
Deferred Revenue Growth: Both current and noncurrent deferred revenue balances increased over time, indicating expanding subscription or contract liabilities that could convert to future revenue.
Increased Operating Capital Used: There have been fluctuations in changes in operating assets and liabilities; notable negative adjustments in some quarters indicate working capital increases could absorb cash temporarily.
Investment in Property, Plant & Equipment and Acquisitions: Capital expenditures and acquisitions contribute to investing cash outflows, which have been sizeable in some quarters (up to $55 million for acquisitions in Q1 2023), potentially impacting free cash flow.

Summary: Doximity showcases a strong growth trajectory supported by rising revenue, expanding profitability, and notable cash flow generation. The company invests actively in marketing and R&D to fuel continued growth, while maintaining a solid liquidity position. Investors should consider ongoing investments and share repurchase activities that influence cash flow profiles. Overall, Doximity’s financial trends reflect a healthy and growing business well-positioned for future expansion in the healthcare technology sector.

10/24/25 01:52 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Doximity's Financials

When does Doximity's fiscal year end?

According to the most recent income statement we have on file, Doximity's financial year ends in March. Their financial year 2024 ended on March 31, 2024.

How has Doximity's net income changed over the last 4 years?

Doximity's net income appears to be on an upward trend, with a most recent value of $147.58 million in 2024, rising from $29.74 million in 2020. The previous period was $112.82 million in 2023. View Doximity's forecast to see where analysts expect Doximity to go next.

What is Doximity's operating income?

Doximity's total operating income in 2024 was $163.88 million, based on the following breakdown:

Total Gross Profit: $424.75 million
Total Operating Expenses: $260.88 million

How has Doximity's revenue changed over the last 4 years?

Over the last 4 years, Doximity's total revenue changed from $116.39 million in 2020 to $475.42 million in 2024, a change of 308.5%.

How much debt does Doximity have?

Doximity's total liabilities were at $177.98 million at the end of 2024, a 4.2% increase from 2023, and a 71.9% increase since 2021.

How much cash does Doximity have?

In the past 3 years, Doximity's cash and equivalents has ranged from $66.39 million in 2021 to $158.03 million in 2023, and is currently $96.79 million as of their latest financial filing in 2024.

How has Doximity's book value per share changed over the last 4 years?

Over the last 4 years, Doximity's book value per share changed from 0.00 in 2020 to 4.83 in 2024, a change of 483.2%.

Related Companies

This page (NASDAQ:DOCS) was last updated on 10/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Doximity (DOCS) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Doximity's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Doximity (DOCS) Financials

Annual Income Statements for Doximity

Quarterly Income Statements for Doximity

Annual Cash Flow Statements for Doximity

Quarterly Cash Flow Statements for Doximity

Annual Balance Sheets for Doximity

Quarterly Balance Sheets for Doximity

Annual Metrics And Ratios for Doximity

Quarterly Metrics And Ratios for Doximity

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Doximity's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools